Press News

2017.02.16：
Tella Pharma to Open Clinical Trial Manufacturing Facility in March Located at the Development Center for Regenerative Medicine and Cell Therapy Established by Kanagawa Prefecture.
2015.09.16：
tella Signed Client Medical Institution Agreement with Ageo Central General Hospital
2015.07.16：
Start of Research for Establishing Dendritic Cells Derived from Human iPS Cells~ Joint research agreement signed with Jikei University School of Medicine Malignant TumorTreatment Research Department ~
2015.04.03：
Clinical Results for Dendritic Cell Vaccine Vaccell® Announced in Cancer Science~Evaluation of the feasibility and immune response of Vaccell® pulsed with WTI peptides for treating advanced pancreatic cancer~
2015.03.17：
An Exclusive License Received for Immune Cell Cryopreservation Solution,a Key Technology for Regenerative and Cell Medicine,in a Step Toward Vaccell® Regulatory Approval
2014.07.30：
Clinical Results for DC Vaccine Vaccell® Announced in Clinical Cancer Research —Evaluation for the safety and efficacy of DC vaccine Vaccell® pulsed with WT1 class I peptide and class II peptide for treating advanced pancreatic cancer—
2014.07.10：
tella and Medical Corporation Isokai (Seren Clinic Tokyo) to Begin Joint Clinical Study for the DC Vaccine Vaccell® Using the New Cancer Antigens Survivin Peptides and MAGE-A4 Peptides
2014.07.01：
Two Patents Related to NK Cells, Jointly Applied with Kyushu University, was Approved —Successful Manufacture of High-Performance NK Cells (ZNK® Cells) From a Variety of Cell Sources—
2014.06.16：
Patent for Next-generation Cancer Antigens Survivin Peptides Approved in Japan and Australia
2014.06.16：
Patent for Next-generation Cancer Antigens MAGE-A4 Peptides Approved in Japan
2014.06.11：
Tokyo Women’s Medical University to Start Phase I and II Clinical Studies for NK Cell Therapy for Malignant Lymphoma
2014.05.27：
Clinical Results for DC Vaccine Vaccell® Announced in Journal of Ovarian Research
2014.05.12：
Clinical Results for DC Vaccine Vaccell® Announced in Cancer Immunology, Immunotherapy
2014.04.08：
Notice Regarding Capital and Business Alliance with Kohjin Bio
2014.02.07：
Notice Regarding Establishment of a Jointly Owned Subsidiary
2013.12.19：
Notice of Adjustment of Exercise Price
2013.12.10：
Notice Regarding the Establishment of a Subsidiary– Aiming to receive approval for the DC vaccine Vaccell® as Japan’s first cell immunotherapy drug –
2013.12.05：
Healios and tella Signed Memorandum of Agreement for the Business Alliance–Aiming to develop cancer immunotherapy using iPS cells–
2013.10.04：
tella Signs Joint Research Agreement with Kitasato Institute (Kitasato University Kitasato Institute Hospital)-Phase I clinical study on DC vaccine therapy using cancer antigens for treating hepatocellular carcinoma-
2013.08.12：
tella Establishes an Alliance with Medical Corporation Hakutokai, Hakutokai Takao Hospit
2013.08.06：
tella Establishes an Alliance with Kitasato Institute (Kitasato University Kitasato Institute Hospital)
2013.08.06：
Results of DC Vaccine Therapy Clinical Trials Announced in Journal of Gastrointestinal Surgery Study involves the effectiveness and prognosis factors of the DC vaccine therapy for treating unresectable advanced recurrent biliary tract cancer
2013.08.06：
Technology for culturing NK cells developed jointly with Kyushu University reported in Human Gene Therapy Methods -tella establishes technology for culturing ZNK® cells that are highly effective in killing cancer cells
2013.07.17：
Development of New Immunotherapy for Autoimmune Diseases and Allergies by Using a New Technology That Utilizes the Effects of Dendritic Cells (DC)～tella receives exclusive right for use of technology concerning regulatory DC～
2013.05.31：
Notice of Third-party Allotment of No. 8 to No. 11 Issues of Stock Acquisition Rights
2013.05.02：
Notice regarding the Establishment of a Subsidiary New Entry into ‘Imaging CRO’ Clinical Trial Support Business Using the Latest Imaging Technology and Concentrating in New Anti-cancer Treatments
2013.04.16：
tella Signs Joint Research Agreement with Kyushu University Agreement marks the beginning of pharmaceutical development activities using the DC vaccine
2013.04.09：
Notice Regarding Equity Investment in Retina Institute Japan A stock subscription agreement has been concluded with Retina Institute Japan, one of the RIKEN Ventures aiming to commercialize the world’s first practical applications of iPS cell technology.
2012.10.30：
Shinshu University Hospital Approved as a Medical Institution Providing DC Vaccine Therapy as an Advanced Medical Treatment
2012.09.20：
Patent for Next-generation Cancer Antigens MAGE-A4 Peptides Approved in United States
2012.08.21：
New Region Added for Exclusive Rights for WT1 Peptides Patent and Expiration Date Extended
2011.11.15：
Notice Regarding Issuance of New Shares by way of Third-party Allotment
2011.11.07：
Collaborative Clinical Study for Advanced Melanoma Starts with Keio University School of Medicine～Phase 1 and 2 clinical studies for a of DC vaccine therapy with anti-cancer drugs～
2011.11.07：
Collaborative Clinical Study for Advanced and Recurrent Esophageal Cancer Starts with Keio University School of Medicine～Phase 1 clinical study on WT1 peptide pulsed DC vaccine therapy in combination with anticancer drugs～
2011.10.12：
tella Signs Joint Research Agreement with the National Center for Global Health and Medicine～For introduction of DC vaccine therapy to collect and analyze clinical data～
2011.09.30：
Joint R&D with Asahi Kasei for Cell Processing Equipment for Cancer Treatment ～Contributing to cancer treatment with cell therapy and regenerative medicine～

TopPage